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Coffee, a major dietary source of caffeine, is amongst the most widely consumed beverages 
in the world and has received considerable attention regarding health risks and benefits. We 
conducted a genome-wide(GW) meta-analysis of predominately regular-type coffee 
consumption (cups/day) among up to 91,462 coffee consumers of European ancestry with 
top single-nucleotide polymorphisms (SNPs) followed-up in ~30,062 and 7,964, coffee 
consumers of European and African American ancestry, respectively. Studies from both 
stages were combined in a trans-ethnic meta-analysis. Confirmed loci were examined for 
putative functional and biological relevance. Eight loci, including six novel loci, met GW-
significance (log10Bayes-factor>5.64) with per allele effect sizes of 0.03-0.14 cups/day. Six 
are located in or near genes potentially involved in pharmacokinetics (ABCG2, AHR, POR, 
CYP1A2) and pharmacodynamics (BDNF, SLC6A4) of caffeine. Two map to GCKR and 
MLXIPL, genes related to metabolic traits but lacking known roles in coffee consumption. 
Enhancer and promoter histone marks populate the regions of many confirmed loci and 
several potential regulatory SNPs are highly correlated with the lead SNP of each. SNP 
alleles near GCKR, MLXIPL, BDNF and CYP1A2 that were associated with higher coffee 
consumption have previously been associated with smoking initiation, higher adiposity and 
fasting insulin and glucose but lower blood pressure and favorable lipid, inflammatory and 
liver enzyme profiles (P<5×10−8).Our genetic findings among European and African 
American adults reinforce the role of caffeine in mediating habitual coffee consumption and 
may point to molecular mechanisms underlying inter-individual variability in 
pharmacological and health effects of coffee.
INTRODUCTION
Coffee is amongst the most widely consumed beverages in the world1. North American 
coffee drinkers typically consume ~2 cups per day while the norm is at least 4 cups in many 
European countries1. In prospective cohort studies, coffee consumption is consistently 
associated with lower risk of Parkinson’s disease, liver disease and type 2 diabetes2. 
However, the effects of coffee on cancer development, cardiovascular and birth outcomes 
and other health conditions remain controversial2. For most populations, coffee is the 
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primary source of caffeine, a stimulant also present in other beverages, foods and 
medications1, 3. The fifth edition of the Diagnostic and Statistical Manual of Mental 
Disorders does not include a diagnosis of caffeine dependence or abuse due to a paucity of 
evidence but lists caffeine intoxication and withdrawal as Disorders4. Knowledge of factors 
contributing to coffee’s consumption and physiological effects may greatly advance the 
design and interpretation of population and clinical research on coffee and caffeine5. Genetic 
factors could be especially valuable as they offer ways to study the potential health effects of 
coffee via instrumental variables or gene-environment interactions5. Heritability estimates 
for coffee and caffeine use range between 36 and 58%6. Genome-wide association studies 
(GWAS) of habitual caffeine and coffee intake have identified variants near CYP1A2 and 
AHR7-9. Cytochrome P450 (CYP)1A2 is responsible for ~95% of caffeine metabolism in 
humans and aryl hydrocarbon receptor (AHR) plays a regulatory role in basal and substrate-
induced expression of target genes, including CYP1A1 and CYP1A210, 11.
To identify additional loci, we conducted a staged GW meta-analysis of coffee consumption 
including over 120,000 coffee consumers sourced from population-based studies of 
European and African American ancestry.
MATERIALS AND METHODS
Study design and populations
Supplementary Figure S1 depicts an overview of the current study. We performed a meta-
analysis of GWAS summary statistics from 28 population-based studies of European 
ancestry to detect single-nucleotide polymorphisms (SNPs) that are associated with coffee 
consumption. Top loci were followed-up in studies of European (13 studies) and African 
American (7 studies) ancestry and confirmed loci were explored in a single Pakistani 
population. Detailed information on study design, participant characteristics, genotyping and 
imputation for all contributing studies are provided in the Supplementary Information and 
Supplementary Tables S1-S6.
Phenotype
All phenotype data were previously collected via interviewer- or self-administered 
questionnaires (Supplementary Table S1). Our primary phenotype (‘phenotype 1’) was cups 
of predominately regular-type coffee consumed per day among coffee consumers. Coffee 
data collected categorically (e.g. 2-3 cups/day) was converted to cups/day by taking the 
median value of each category (e.g. 2.5 cups/day). A secondary analysis was performed 
comparing high to infrequent/non- coffee consumers (‘phenotype 2’). A subset of stage 1 
studies collected information on decaffeinated coffee consumption; which was examined in 
follow-up analysis of the confirmed loci.
Statistical analysis
Each stage 1 (discovery) study performed GWA-testing for each phenotype across ~2.5 
million genotyped or imputed autosomal SNPs (HapMap II, Centre d’Etude du 
Polymorphisme Humain [CEU] reference), based on linear (cups/day, phenotype-1) or 
logistic (high vs. none/low, phenotype-2) regression under an additive genetic model. 
et al. Page 2
Mol Psychiatry. Author manuscript; available in PMC 2016 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Analyses were adjusted for age, smoking status and, when applicable, sex, case-control 
status, study-site, family structure and/or study specific principal components of population 
substructure (Supplementary Table S7). SNPs with minor allele frequency (MAF) <0.02 or 
with low imputation quality scores were removed prior to meta-analysis (Supplementary 
Table S5). The GWAtoolbox (see Supplementary Information for URLs) was used for initial 
quality control. MAFs and a plot comparing (1/median standard error of effect size) vs. 
(square root of sample size) for each study were also reviewed for outliers and these were 
addressed prior to the final meta-analysis.
For both phenotypes, GW meta-analysis was conducted using a fixed effects model and 
inverse-variance weighting with a single genomic control (GC) correction as implemented in 
METAL12 and GWAMA13 (r>0.99 for correlation between METAL and GWAMA results). 
The phenotypic variance explained by additive SNP effects was estimated in the Women’s 
Genome Health Study (WGHS, n=15,987 with identity-by-state <0.025) using GCTA 14. 
Stage 1 summary statistics were also subject to pathway analysis using MAGENTA15 
(Supplementary Information).
For regions achieving association P values <5×10−8 (7p21, 7q23.11, 11p13, 15q24) we 
performed conditional analysis using the summary statistics from the meta-analysis to test 
for the association of each SNP while conditioning on the top SNPs, with correlations 
between SNPs due to linkage disequilibrium (LD) estimated from the imputed genotype data 
from the Atherosclerosis Risk in Communities cohort16, a large and representative cohort of 
men and women of European ancestry.
Our approach to selecting SNPs for replication (stage 2) is described in Supplementary 
Information. Stage 2 meta-analyses were performed separately for European and African 
American populations, using the same statistical models and methods as described for stage 
1, but without GC (Supplementary Information).
Studies from all stages were included in an overall meta-analysis using Meta-ANalysis of 
TRans-ethnic Association studies (MANTRA)17; which adopts a Bayesian framework to 
combine results from different ethnic groups by taking advantage of the expected similarity 
in allelic effects between the most closely related populations. MANTRA was limited to 
SNPs selected for replication thus no GC was applied. A random effects analysis using 
GWAMA was performed in parallel to obtain effect estimates, which are not generated by 
MANTRA. The GW-significance threshold of log10 BF >5.64 approximates a traditional 
GW P-value threshold of 5×10−8 under general assumptions18, 19. Subgroup analysis and 
meta-regression were performed to investigate possible sources of between-study 
heterogeneity (Supplementary Information). Fine-mapping: To assess the improvement in 
fine-mapping resolution due to trans-ethnic meta-analysis we applied the methods of 
Franceschini et al 17 to stage 1 and stage 2 (African Americans only) GW-summary level 
data (Supplementary Information).
Potential SNP-function and biological and clinical inferences
Details pertaining to follow-up of confirmed loci are provided in the Supplementary 
Information. Briefly, all confirmed index SNPs and their correlated proxies were examined 
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for putative function using publicly available resources. Bioinformatics and computational 
tools were used to systematically mine available knowledge and experimental databases to 
inform biological hypotheses underlying the link between loci and coffee consumption as 
well as connections between loci. For these analyses all genes mapping to the confirmed 
regions were considered potential candidates. Finally, we searched the National Human 
Genome Research Institute GWAS catalogue20 and Metabolomics GWAS server 21 for all 
GW-significant associations with our confirmed coffee-SNPs. Complete GWAS summary 
data for coffee-implicated diseases or traits were additionally queried.
RESULTS
SNPs associated with coffee consumption
Discovery stage—Results from the discovery stage are summarized in Supplementary 
Figs S2-S5. Little evidence for genomic inflation (<1.07) was observed for either phenotype. 
The two analyses yielded similarly ranked loci and significant enrichment of ‘xenobiotic’ 
genes (MAGENTA’s FDR<0.006), suggesting no major difference in the genetic influence 
on coffee drinking initiation compared with the level of coffee consumption among coffee 
consumers at these loci. Overall, approximately 7.1% (standard error: 2%) of the variance in 
coffee cups consumed per day (phenotype-1) could be explained by additive and common 
SNP effects in the WGHS.
Conditioning on the index SNPs of each region achieving association P values <5×10−8 
(7p21, 7q23.11, 11p13, 15q24) in the discovery stage provided little evidence for multiple 
independent variants (Supplementary Figure S6). Only four of the SNPs on chromosome 7 
were potentially independent and carried forward with other promising SNPs.
Replication and trans-ethnic meta-analysis—Forty-four SNPs spanning 33 genomic 
regions met significance criteria for candidate associations and were followed-up in stage 2 
(Supplementary Tables S8-S13). Eight loci, including six novel, met our criteria for GW-
significance (log10 BF>5.64) in a trans-ethnic meta-analysis of all discovery and replication 
studies (Table 1, Supplementary Tables S14-S16, Supplementary Figs S7 and S8). 
Confirmed loci have effect sizes of 0.03-0.14 cups/day per allele and together explain ~1.3% 
of the phenotypic variance of coffee intake. We were underpowered to replicate these 
associations in a Pakistani population (Supplementary Information).
Functional and biological inferences
Enhancer (H3K4me1) and promoter (H3K4me3) histone marks densely populate many of 
these regions and several nonsynonymous and potential regulatory SNPs are highly 
correlated (r2>0.8) with the lead SNP and thus strong candidates for being a causal variant 
(Table 2, Supplementary Information, Supplementary Tables S17-S19). Candidate genes 
form a highly connected network of interactions, featuring discernible clusters of genes 
around BDNF and AHR (Figure 1, Supplementary Information, Supplementary Tables S20 
and S21). At least one gene in each of the eight regions i) is highly expressed in brain, liver 
and/or taste buds, ii) results in phenotype abnormalities relevant to coffee consumption 
behavior when modified in mice, and iii) is differentially expressed in human hepatocytes 
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when treated with high (7500 M) but not low (1500 M) doses of caffeine (Table 2, 
Supplementary Tables S22-S24).
Additional genomic characterization of the top loci allows further biological inference as 
follows:
i. Previously identified loci near AHR (7p21) and CYP1A2 (15q24)
Consistent with previous reports in smaller samples7-9, the intergenic 7p21 and 
15q24 loci near AHR and CYP1A1/CYP1A2 respectively remained the most 
prominent and highly heterogeneous loci associated with coffee consumption. The 
same index SNPs were identified in European and African Americans suggesting 
they are robust HapMap proxies for causal variants in these two populations. 
Cohort-wide mean coffee consumption explained part of the heterogeneity in study 
results for both loci (Supplementary Table S25, Supplementary Information). The 
rs2472297 T and rs4410790 C alleles associated with increased coffee consumption 
have recently been associated with lower plasma caffeine levels 21 and shown to 
increase CYP1A2-mediated metabolism of olanzapine22. The C allele of rs4410790 
is also positively correlated with cerebellum AHR methylation, suggesting a novel 
role of Ahr in motor or learning pathways that may trigger coffee consumption. 
The most significant variants at 15q24 reside in the CYP1A1-CYP1A2 bidirectional 
promoter where AHR response elements have been identified and shown to be 
important for transcriptional activation of both CYP1A1 and CYP1A223. The 
rs2472297 T variant putatively weakens the binding of SP1, a co-activator in the 
Ahr-Arnt complex regulating CYP1 locus transcription24 and is also implicated in 
the expression of several neighboring genes. The latter observation, together with 
this region’s high LD and long range chromatin interactions (Supplementary Figure 
S9), suggests a regulatory network among these genes.
ii. Novel loci at 7q11.23 (POR) and 4q22 (ABCG2) likely function in caffeine 
metabolism
Variants at 7q11.23 (rs17685) and 4q22 (rs1481012) map to novel yet biologically 
plausible candidate genes involved in xenobiotic metabolism. rs17685 maps to the 
3′UTR of POR, encoding P450 oxidoreductase which transfers electrons to all 
microsomal CYP450s enzymes25. The rs17685 A variant associated with higher 
coffee consumption is linked to increased POR expression and potentially weakens 
the DNA binding of several transcriptional regulatory proteins including 
BHLHE40, which inhibits POR expression26. The same SNP is in LD (CEU: 
r2=0.93) with POR*28 (rs1057868, Ala503Val), which is associated with 
differential CYP activity depending on the CYP isoform, substrate and 
experimental model used27. rs1481012 at 4q22 maps to ABCG2, encoding a 
xenobiotic efflux transporter. rs1481012 is in LD (CEU: r2=0.92) with rs2231142 
(Gln141Lys), a functional variant at an evolutionarily constrained residue28. 
However, fine-mapping of this region on the basis of reduced LD in the African 
American sample limited an initial 189102 kb region to a credible span of 6249 kb 
(Supplementary Table S16), that excluded rs2231142.
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iii. Novel loci at 11p13 (BDNF) and 17q11.2 (‘SLC6A4’) likely mediate the positive 
reinforcing properties of coffee constituents
The index SNP at 11p13 is the widely investigated missense mutation (rs6265, 
Val66Met) in BDNF (Supplementary Table S26). Brain-derived neurotrophin 
factor (BDNF) modulates the activity of serotonin, dopamine and glutamate, 
neurotransmitters involved in mood-related circuits and plays a key role in memory 
and learning29. The Met66 allele impairs neuronal activity-dependent BDNF 
secretion30 and thus may attenuate the rewarding effects of coffee and, in turn, 
motivation to consume coffee. The increasingly recognized roles of BDNF in the 
chemosensory system and conditioned taste preferences may also be relevant31. 
The index SNP (rs9902453) at 17q11.2 maps to the EFCAB5 gene and is in LD 
(CEU: r2>0.8) with SNPs that alter regulatory motifs for AhR32 in the neighboring 
gene NSRP1, but neither gene is an obvious candidate for coffee consumption. 
Upstream of rs9902453 lies a possibly stronger candidate: SLC6A4 encoding the 
serotonin transporter. Serotonergic neurotransmission affects a wide range of 
behaviors including sensory processing and food-intake33.
iv. Novel loci at 2p24 (GCKR) and 17q11.2 (MLXIPL)
Variants at 2p24 (rs1260326) and 7q11.23 (rs7800944) map to GCKR and 
MLXIPL, respectively. The former has been associated with plasma glucose and 
multiple metabolic traits and the latter with plasma triglycerides (Table 3, 
Supplementary Table S27). Adjustment of regression models for plasma lipids in 
the Women’s Genome Health Study (WGHS, n~17,000) and plasma glucose in 
TwinGene (n~8,800) did not significantly change the relationship between SNPs at 
these two loci and coffee consumption (P>0.48, Supplementary Tables S28 and 
S29). The rs1260326 T allele encodes a nonsynonymous change in the encoded, 
glucokinase regulatory protein (GKRP) leading to increased hepatic glucokinase 
activity34. GKRP and glucokinase may also cooperatively function in the glucose-
sensing process of the brain35 that may, in turn, influence central pathways 
responding to coffee constituents. A direct link between MLXIPL and coffee 
consumption remains unclear, except for the interactions with other candidate 
genes (Figure 1). Experimental evidence and results from formal prioritization 
analyses also warrants consideration of other candidates in these regions (Table 2, 
Figure 1, Supplementary Tables S23, S26, S30, S31). For example, in the frontal 
cortex, the rs1260326 allele positively associated with coffee consumption 
correlates with lower methylation of PPM1G; a putative regulatory target for AhR 
and binding target for PPP1R1B, which mediates psychostimulant effects of 
caffeine36.
Pleiotropy and clinical inferences
None of the eight loci was significantly associated with caffeine taste-intensity (P>0.02) or 
caffeine-induced insomnia (P>0.08), according to previously published GWAS of these 
traits 37-39. SNPs near AHR associated with higher coffee consumption were also 
significantly associated with higher decaffeinated coffee consumption (~0.05 cups/day, 
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P<0.0004, n=24,426); perhaps a result of Pavlovian conditioning among individuals 
moderating their intake of regular coffee or the small amounts of caffeine in decaffeinated 
coffee1.
Across phenotypes in the GWAS catalog20, the alleles leading to higher coffee consumption 
at 2p24, 4q22, 7q11.23, 11p13 and 15q24 have been associated with one or more of the 
following: smoking initiation, higher adiposity and fasting insulin and glucose but lower 
blood pressure and favorable lipid, inflammatory and liver enzyme profiles (P<5×10−8, 
Table 3, Supplementary Table S27). Focused on metabolic, neurologic and psychiatric traits 
for which coffee has been implicated (Table 3, Supplementary Table S32), there were 
additional sub-GW significant associations in published GWAS. Variants associated with 
higher coffee consumption increased adiposity (rs1481012, P=4.85×10−3), birth weight 
(rs7800944, P=2.10×10−3), plasma high-density lipoprotein (HDL, rs7800944, 
P=2.24×10−3), risk of Parkinson’s disease (rs1481012, P=7.11×10−3), reduced blood 
pressure (rs6265, P=6.58×10−4; rs2472297, P<6.80×10−5 and rs9902453, P=6.05×10−3), 
HDL (rs6968554, P=1.18×10−3), risk of major depressive disorder (rs17685, P=6.98×10−3) 
and bipolar disorder (rs1260326, P=2.31×10−3). Associations with adiposity, birth weight, 
blood pressure, HDL and bipolar disorder remain significant after correcting for the number 
of SNPs tested.
DISCUSSION
Coffee’s widespread popularity and availability has fostered public health concerns of the 
potential health consequences of regular coffee consumption. Findings from epidemiological 
studies of coffee consumption and certain health conditions remain controversial2. 
Knowledge of genetic factors contributing to coffee’s consumption and physiological effects 
may inform the design and interpretation of population and clinical research on coffee5. In 
the current report, we present results of the largest GWAS of coffee intake to-date and the 
first to include populations of African American ancestry. In addition to confirming 
associations with AHR and CYP1A2, we have identified six new loci, not previously 
implicated in coffee drinking behavior.
Our findings highlight an important role of the pharmacokinetic and pharmacodynamic 
properties of the caffeine component of coffee underlying a genetic propensity to consume 
the beverage. Loci near BDNF and SLC6A4 potentially impact consumption behavior by 
modulating the acute behavioral and reinforcing properties of caffeine. Others near AHR, 
CYP1A2, POR, and ABCG2 act indirectly by altering the metabolism of caffeine and thus 
the physiological levels of this stimulant. The strength of these four associations with coffee 
intake, along with results from pathway analysis showing significant enrichment for 
‘xenobiotic’ genes, emphasize an especially pronounced role of caffeine metabolism in 
coffee drinking behavior. The current study is the first to link GCKR and MLXIPL variation 
to a behavioral trait. The nonsynonymous rs1260326 SNP in GCKR has been a GW-signal 
for various metabolic traits particularly those reflecting glucose-homeostasis (Table 3). 
GCKR variation may impact the glucose-sensing process of the brain35 that may, in turn, 
influence central pathways responding to coffee constituents. mQTL and binding motif 
analysis suggests PPM1G may be another candidate underlying the association between 
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rs1260326 and coffee consumption. Variants near MLXIPL have also topped the list of 
variants associated with plasma triglycerides (Table 3), but their link to coffee consumption 
remains unclear. Future studies on the potential pleiotropic effects of these two loci are 
clearly warranted. Interestingly, several candidate genes implicated in coffee consumption 
behavior, but not confirmed in our GWAS, interact with one or more of the eight confirmed 
loci (Figure 1). While these findings are encouraging for ongoing efforts they also 
emphasize the need to study sets or pathways of genes in the future.
Specific SNPs associated with higher coffee consumption have previously been associated 
with smoking initiation, higher adiposity and fasting insulin and glucose but lower blood 
pressure and favorable lipid, inflammatory and liver enzyme profiles. Whether these 
relationships reflect pleiotropy, confounding, or offer insight to the potential causal role 
coffee plays in these traits merits further investigation. Future research, particularly 
Mendelian Randomization and gene-coffee interaction studies, will need to consider the 
direct and indirect roles that each SNP has in altering coffee drinking behavior as well as the 
potential for interactions between loci (Figure 1). The heterogeneous effects specific to 
AHR- and CYP1A2-coffee associations point to SNP-specific interactions with the 
environment or population characteristics that might also warrant consideration 
(Supplementary Information).
The strong cultural influences on norms of coffee drinking may have reduced our power for 
loci discovery. This might, in part, underlie our lack of replication in a Pakistani population, 
wherein coffee consumption is extremely rare. Methodological limitations specific to our 
approach may also have reduced our power for loci discovery or precision in estimating 
effect sizes (Supplementary Information). For example, some studies collected coffee data in 
categories of cups/day (e.g. 2-3 cups/day) rendering a less precise record of intake as well as 
a non-Gaussian distributed trait for analysis. The precise chemical composition of different 
coffee preparations is also not captured by standard FFQs and is likely to vary within and 
between populations. Nevertheless, the eight loci together explain ~1.3% of the phenotypic 
variance, a value at least as great as that reported for smoking behavior and alcohol 
consumption which are subject to similar limitations in GWAS40, 41.
The additive genetic variance (or narrow-sense heritability) of coffee intake as estimated by 
GCTA in WGHS (7%) is considerably lower than estimates based on pedigrees (36 to 
57%) 6. The marked discrepancies between the GCTA and pedigree estimates of heritability 
may be due to one or more of the following: the potential contribution of rare variants to 
heritability (not captured by GCTA’s ‘chip-based heritability’), biases in pedigree analysis 
resulting in overestimates of heritability, differences in phenotype ascertainment or 
definition, and cultural differences in the populations studied42.
In conclusion, our results support the hypothesis that metabolic and neurological 
mechanisms of caffeine contribute to coffee consumption habits. Individuals adapt their 
coffee consumption habits to balance perceived negative and reinforcing symptoms that are 
affected by genetic variation. Genetic control of this potential ‘titrating’ behavior would 
incidentally govern exposure to other potentially ‘bioactive’ constituents of coffee that may 
be related to the health effects of coffee or other sources of caffeine. Thus, our findings may 
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point to molecular mechanisms underlying inter-individual variability in pharmacological 
and health effects of coffee and caffeine.
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Figure 1. 
Network describing direct interactions between candidate genes of confirmed loci. 
Relationships were retrieved from databases of transcription regulation and protein-protein 
interaction experiments (Supplementary Table S21). Genes are represented as nodes that are 
colored according to locus. Candidate genes for loci identified in the current study were 
supplemented with known candidate genes related to caffeine pharmacology (grey nodes). 
Edges indicate known interactions.
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Table 3
Associations between coffee consumption loci and other traits
Lead SNP,
allele ↑ coffee
consumptiona
closest gene
Other Traitsb
higher levels/riskc lower levels/riskc
rs1260326, C
GCKR
non-albumin protein
fasting glucose
HOMA-IR
fasting insulin
mannose
serum albumin
2-hr glucose challenge
metabolic syndrome
glucose/mannose ratio
total cholesterol
triglycerides
hypertriglyceridemia
chronic kidney disease
uric acid
SHBG Crohn’s disease
C-reactive protein
platelet counts
GGT docosapentaenoic acid
alanine/glutamine ratio
alanine
LDL (P=2.33×10−4)
waist-to-hip-ratio (P=3.40×10−4)
bipolar disorder (P=2.31×l0−3)
rs1481012, A
ABCG2
LDL response to statins (‘responders’)
uric acid
body mass index (P=4.85×10−3)
rs6968554 , G
AHR
caffeine
HDL (P=1.18×10−3)
rs7800944, C
MLXIPL
triglycerides
HDL (P=2.24×10−3)
birth weight (P=2.10×10−3)
rs6265, C
BDNF
smoking initiation
body mass index
DBP (P=6.58×10−4)
rs2472297d, T
CYP1A1_CYP1A2
caffeine e
SBP (P=6.81×10−5)
DBP (P=6.75×10−6)
rs9902453,G
EFCAB5
SBP (P=6.05×10−3)
Abbreviations: DBP, diastolic blood pressure; GGT, gamma-glutamyltransferase; HDL, high density lipoprotein; LDL, low density lipoprotein; 
SBP, systolic blood pressure; SHBG, sex hormone binding globulin
a
Lead SNP-allele associated with higher coffee consumption.
b
Traits associated with lead SNP (or close proxies: r2>0.80) according to previous GWAS20(Shin et al, 2014). Grey cells denote all GW-
significant significant associations (P<5.00 ×l0−8 20 or P<1.03 ×l0−10 (Shin et al, 2014) and white cells denote coffee-relevant trait associations 
(P<;6.25×l0−3). See Supplementary Information for details and references to original GWAS.
c
Relative to allele associated with higher coffee consumption.
d
rsl378942 A, also associated with higher coffee consumption (P< 1.46×10−17) in stage 1 of the current report but in low LD with rs2472297 
(CEU: r2=0.10), was previously associated with lower DBP in GWAS (P<5,00× 10−8).
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e
Borderline significant (P<1.51 ×10−10) according to Shin et al21.
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